Khemetic Nation News Network | Science Desk
Science Explainer | October 14, 2026
How do chemical signals connect the brain with the rest of the body? Candace B. Pert’s research on neuropeptides helped frame that question in molecular terms. Bruce H. Lipton’s work on cultured cells, and his later writing about belief, approaches a related question: how does a cell respond to its surroundings?
Their work offers an entry into the biology of communication. Understanding it requires separating receptor experiments, cell-culture findings and clinical trials from the larger interpretations offered to popular audiences. This article revisits historical research; it does not report a newly announced discovery or a joint Pert–Lipton study.
Pert’s neuropeptides and the brain–body network
Peptides are chains of amino acids. Neuropeptides are peptide messengers involved in nervous-system signaling; their effects depend on receptors and the biological context in which those receptors operate.
In the 1985 paper Neuropeptides and Their Receptors: A Psychosomatic Network, Pert, Michael R. Ruff, Richard J. Weber and Miles Herkenham described peptide signaling across the brain, glands and immune system. The paper combined evidence about receptor distribution with a proposed framework for communication between these systems.
The authors suggested that this network could contribute to the biochemical basis of emotion. That was a broader interpretation of the evidence, rather than a clinical demonstration that a particular thought could cure an illness. The paper was not a randomized trial of emotional practices.
A measurable example: immune-cell movement
A separate 1985 study by Ruff, Schiffmann, Terranova and Pert examined human monocytes and small-cell lung carcinoma cells. It reported that bombesin, a neuropeptide, could attract these cells along a chemical gradient. Relationships between peptide activity and receptor binding supported a receptor-mediated mechanism.
This is chemotaxis: directed cell movement in response to a chemical signal. The authors proposed possible implications for metastasis. Laboratory observations of cell movement do not by themselves establish how a person’s emotions affect cancer progression, and the study did not test a cancer treatment in patients.
Lipton’s research: the chemical environment of cells
Lipton, Klaus G. Bensch and Marvin A. Karasek published Microvessel Endothelial Cell Transdifferentiation: Phenotypic Characterization in 1991. They studied cultured human skin microvessel endothelial cells—the cells associated with the lining of small blood vessels.
The abstract describes changes in cell characteristics under culture conditions involving cyclic AMP, or cAMP, and histamine. Certain transitional cells returned to an epithelial-like state when supplied with cAMP. The investigators reported that changes could occur without cell division.
This experiment illustrates responsiveness to chemical conditions. It was not a test of people’s beliefs, emotions or meditation. Neither cAMP nor histamine is a peptide, and the study should not be presented as a shared peptide discovery by Lipton and Pert. The accessible abstract does not specify a donor sample size or establish clinical effectiveness.
Where belief and epigenetics enter the discussion
In a March 2021 essay, Lipton argues that perceptions influence the body’s internal chemistry and, through that environment, affect cellular responses. His discussion connects hormones and neuropeptides with his broader interpretation of belief and biology.
There is an established scientific field studying regulation beyond DNA sequence. The National Human Genome Research Institute defines epigenetics in terms of chemical modifications affecting gene activity without changing the underlying sequence. Its epigenomics fact sheet explains that environmental exposures and lifestyle factors can influence those modifications.
Those mechanisms do not establish unlimited conscious control over genes. Lipton’s broader claims about belief require evidence addressing the specific claim; they cannot be treated as conclusions automatically demonstrated by his cell-culture experiment.
Why clinical trials matter: the peptide T example
Peptide T illustrates the distance between a plausible biological mechanism and an effective treatment. A 1998 randomized, double-blind, placebo-controlled trial investigated HIV-associated cognitive impairment at three sites. It randomized 215 participants; 143 contributed to the defined efficacy analysis.
Over six months, peptide T did not significantly outperform placebo on the primary cognitive endpoints. Additional subgroup analyses suggested possible benefits, but the researchers called for further studies and cautioned about multiple comparisons. Attrition and the use of an efficacy sample rather than an intention-to-treat analysis also limited interpretation.
The lasting question
Pert’s receptor research and Lipton’s cell studies invite careful examination of how biological systems communicate and respond to conditions. Their strongest lesson for readers is methodological: identify what was measured, in which cells or participants, and whether the evidence supports the proposed conclusion.
Editorial note: This explainer compares distinct bodies of work and attributed interpretations. It offers no peptide-treatment protocol or claim that belief cures disease.
Image: Illustrative laboratory photograph by Trnava University via Unsplash; not Pert’s or Lipton’s laboratory.
Sources and further reading
- Pert and colleagues, neuropeptides and receptors, 1985
- Ruff and colleagues, neuropeptide-induced chemotaxis, 1985
- Lipton, Bensch and Karasek, endothelial cell study, 1991
- Lipton’s account of belief and biology, March 2021
- NHGRI epigenomics fact sheet
- Heseltine and colleagues, peptide T clinical trial, 1998
